Validation of MdmX as a therapeutic target for reactivating p53 in tumors

Genes and Development

Volumn 25, Issue 16, 2011, Pages 1746-1757

  Garcia, Daniel ^a   Warr, Matthew R ^b   Martins, Carla P ^c   Swigart, Lamorna Brown ^a   Passegue, Emmanuelle ^b   Evan, Gerard I ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; INHIBITION KINETICS; LIFE EXTENSION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STEM CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EMBRYO, MAMMALIAN; FEMALE; FIBROBLASTS; GENE EXPRESSION; IMMUNOBLOTTING; KAPLAN-MEIER ESTIMATE; LIVER; LYMPHOMA; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS C-MYC; TAMOXIFEN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

MUS;

EID: 84860389276     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.16722111     Document Type: Article

References (54)

1. Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM, You MJ, Hirschi KK, Lozano G. 2010. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 7: 606-617.
2. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lym-phoid malignancy in transgenic mice. Nature 318: 533-538.
3. Barboza J, Iwakuma T, Terzian T, El-Naggar A, Lozano G. 2008. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 6: 947-954.
4. Boesten LS, Zadelaar SM, De Clercq S, Francoz S, van Nieuwkoop A, Biessen EA, Hofmann F, Feil S, Feil R, Jochemsen AG, et al. 2006. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ 13: 2089-2098.
5. Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, et al. 2009. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer 101: 774-781.
6. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, Evan GI. 2005. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37: 718-726.
7. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, et al. 2004. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24: 5835-5843.
8. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC. 2006. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci 103: 3232- 3237.
9. Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. 2006. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 26: 192-198.
10. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. 2002. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 277: 19251-19254.
11. Hedstrom E, Issaeva N, Enge M, Selivanova G. 2009. Tumor-specific induction of apoptosis by a p53-reactivating compound. Exp Cell Res 315: 451-461.
12. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. 2004. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328.
13. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
14. Jackson MW, Lindstrom MS, Berberich SJ. 2001. MdmX binding to ARF affects Mdm2 protein stability and p53 transactiva-tion. J Biol Chem 276: 25336-25341.
15. Junttila M, Karnezis A, Garcia D, Madriles F, Kortlevel R, Rostker F, Brown-Swigart L, Pham D, Seo YR, Evan G, et al. 2010. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468: 567-571.
16. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. 2005. SLAM family receptors distinguish he-matopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121: 1109-1121.
17. Kruse JP, Gu W. 2009. Modes of p53 regulation. Cell 137: 609- 622.
18. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, et al. 2006. In-activation of the p53 pathway in retinoblastoma. Nature 444: 61-66.
19. Leonova KI, Shneyder J, Antoch MP, Toshkov IA, Novototskaya LR, Komarov PG, Komarova EA, Gudkov AV. 2010. A small molecule inhibitor of p53 stimulates amplification of hema-topoietic stem cells but does not promote tumor development in mice. Cell Cycle 9: 1434-1443.
20. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. 2008. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 15: 841-848.
21. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, et al. 2009. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4: 37-48.
22. Liu D, Ou L, Clemenson GD, Chao C, Lutske ME, Zambetti GP, Gage FH, Xu Y. 2010. Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol 12: 993-998.
23. Maetens M, Doumont G, Clercq SD, Francoz S, Froment P, Bellefroid E, Klingmuller U, Lozano G, Marine JC. 2007. Distinct roles of Mdm2 and Mdm4 in red cell production. Blood 109: 2630-2633.
24. Mancini F, Di Conza G, Monti O, Macchiarulo A, Pellicciari R, Pontecorvi A, Moretti F. 2010. Puzzling over MDM4-p53 network. Int J Biochem Cell Biol 42: 1080-1083.
25. Marine J, Jochemsen A. 2005. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 331: 750-760.
26. Marine JC, Dyer MA, Jochemsen AG. 2007. MDMX: from bench to bedside. J Cell Sci 120: 371-378.
27. Martins CP, Brown-Swigart L, Evan GI. 2006. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334.
28. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, Frisen J. 2006. P53 suppresses the self-renewal of adult neural stem cells. Development 133: 363-369.
29. Migliorini D, Lazzerini Denchi E, Danovi D, Jochemsen A, Capillo M, Gobbi A, Helin K, Pelicci PG, Marine JC. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22: 5527-5538.
30. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
31. Morachis JM, Murawsky CM, Emerson BM. 2010. Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes Dev 24: 135-147.
32. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. 2008. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14: 447-457.
33. Okamoto K, Taya Y, Nakagama H. 2009. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett 583: 2710-2714.
34. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29: 92-95.
35. Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, et al. 2010. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 285: 10786-10796.
36. Ringshausen I, Oshea C, Finch A, Swigart L, Evan G. 2006. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10: 501-514.
37. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. 2007. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumori-genesis. Nat Cell Biol 9: 493-505.
38. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, et al. 2008. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci 105: 3933-3938.
39. Sharp DA, Kratowicz SA, Sank MJ, George DL. 1999. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 274: 38189-38196.
40. Stad R, Ramos YF, Little N, Grivell S, Attema J, van Der Eb AJ, Jochemsen AG. 2000. Hdmx stabilizes Mdm2 and p53. J Biol Chem 275: 28039-28044.
41. Sun SH, Zheng M, Ding K, Wang S, Sun Y. 2008. A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther 7: 845-852.
42. TeKippe M, Harrison DE, Chen J. 2003. Expansion of hemato-poietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol 31: 521-527.
43. Uldrijan S, Pannekoek WJ, Vousden KH. 2007. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J 26: 102-112.
44. Valentin-Vega YA, Okano H, Lozano G. 2008. The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ 15: 1772-1781.
45. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
46. Vazquez A, Bond EE, Levine AJ, Bond GL. 2008. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
47. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
48. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
49. Wade M, Wahl GM. 2009. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7: 1-11.
50. Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM. 2009. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell 16: 33-43.
51. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. 2006. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci 103: 3226-3231.
52. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
53. Young NP, Jacks T. 2010. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci 107: 10184-10189.
54. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ. 2003. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci 100: 15930-15935.